Novel multiplex stool-based assay for the detection of early-stage colon cancer in a Chinese population

Table 3 Diagnostic sensitivity, specificity and area under the receiver operating characteristic curve for various indexes

Study population	Index	Sensitivity (%)	Specificity (%)	AUC (95%CI)
Training set	Serum CEA	28.0	100.0	0.640 (0.551-0.729)
(n = 150 subjects)	FIT	64.0	96.0	0.800 (0.726-0.874)
	PAX8_P4	76.0	77.3	0.810 (0.741-0.880)
	RASSF1_P1	50.7	93.3	0.782 (0.709-0.854)
	SFRP2_P1	50.7	86.7	0.697 (0.612-0.782)
	sDNA panel	82.7	77.3	0.866 (0.810-0.923)
	sDNA panel + FIT	86.7	86.7	0.924 (0.881-0.966)
Test set	Serum CEA	32.0	100.0	0.660 (0.552-0.768)
(n = 100 subjects)	FIT	60.0	98.0	0.790 (0.697-0.883)
	sDNA panel	76.0	84.0	0.864 (0.795-0.933)
	sDNA panel + FIT	82.0	96.0	0.909 (0.850-0.967)
Combined set	Serum CEA	29.6	100.0	0.648 (0.580-0.716)
(n = 250 subjects)	FIT	62.4	96.8	0.796 (0.738-0.854)
	sDNA panel	75.2	84.0	0.859 (0.815-0.904)
	sDNA panel + FIT	80.0	93.6	0.918 (0.884-0.952)
Subgroup for stage I	FIT	63.8	96.8	0.803 (0.716-0.891)
(n = 172 subjects)	sDNA panel + FIT	74.5	93.6	0.891 (0.832-0.950)
Subgroup for stage II	FIT	61.5	96.8	0.792 (0.721-0.863)
(n = 203 subjects)	sDNA panel + FIT	83.3	93.6	0.934 (0.899-0.970)

AUC: Area under the receiver operating characteristic curve; CI: Confidence interval; CEA: Carcinoembryonic antigen; FIT: Fecal immunochemical test; sDNA: Stool DNA.